Furthermore, we have shown that loss of phosphorylated (pT371)TRF1 sensitizes cells to Olaparib, a PARP inhibitor potent in killing HR-deficient cancer cells (17), raising the possibility that phosphorylated (pT371)TRF1 might be exploited for cancer therapeutics. This evidence concerns the gene TERF1 and cancer.